Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 4:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 124 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: HIV Infected Individuals Clear all
Completed Not applicable Interventional

Continuous High-Dose Intravenous Dextran Sulfate in Human Immunodeficiency Virus-Infected Individuals

NCT00000684
View directory record Official record
Conditions
HIV Infections
Interventions
Dextran sulfate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
19 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1991
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Sep 10, 2026, 4:40 PM EDT
Completed Phase 4 Interventional Results available

Modulation of Monocyte Activation by Atorvastatin in HIV Infection

NCT01263938
View directory record Official record
Conditions
HIV Dementia
Interventions
Atorvastatin
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 30, 2019 · Synced Sep 10, 2026, 4:40 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Zidovudine for Asymptomatic HIV-Infected Individuals

NCT00000736
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
3,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1995
U.S. locations
43
States / cities
Los Angeles, California • Oakland, California • Palo Alto, California + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Sep 10, 2026, 4:40 PM EDT
Completed Not applicable Interventional

The Effects of Anti-HIV Drugs in HIV-Infected Patients Who Do Not Have AIDS

NCT00001024
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2002
U.S. locations
8
States / cities
Palo Alto, California • San Francisco, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 10, 2026, 4:40 PM EDT
Completed Phase 1 Interventional

A Phase I Study to Evaluate the Immunologic Response and Virologic Impact of AGS-004

NCT02042248
View directory record Official record
Conditions
HIV
Interventions
AGS-004
Biological
Lead sponsor
Cynthia L Gay, MD
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 3, 2017 · Synced Sep 10, 2026, 4:40 PM EDT
Terminated Not applicable Interventional Results available

Raltegravir Cerebrospinal Fluid Pharmacodynamic Study in HIV-Infected Individuals

NCT01293123
View directory record Official record
Conditions
HIV
Interventions
Raltegravir, Efavirenz
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 30, 2019 · Synced Sep 10, 2026, 4:40 PM EDT
Completed Not applicable Interventional

Piloting Eye Movement Desensitization and Reprocessing (EMDR) Therapy in People Living With HIV and Trauma

NCT06730867
View directory record Official record
Conditions
HIV Infected Individuals
Interventions
EMDR Therapy Protocol
Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 23, 2025 · Synced Sep 10, 2026, 4:40 PM EDT
Completed Not applicable Interventional Results available

Elvitegravir (EVG) Cerebrospinal Fluid (CSF) Pharmacokinetics in HIV-Infected Individuals

NCT02251236
View directory record Official record
Conditions
HIV
Interventions
Stribild, Genvoya
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 60 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 30, 2019 · Synced Sep 10, 2026, 4:40 PM EDT
Completed Phase 2 Interventional

A Study of Thymic Humoral Factor (THF Gamma 2) in HIV-Infected Patients

NCT00002435
View directory record Official record
Conditions
HIV Infections
Interventions
Thymic Humoral Factor, Zidovudine
Drug
Lead sponsor
Pharmacia
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
10
States / cities
Irvine, California • Los Angeles, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 10, 2026, 4:40 PM EDT
Completed Phase 2 Interventional Results available

Chloroquine for Reducing Immune Activation in HIV- Infected Individuals

NCT00819390
View directory record Official record
Conditions
HIV Infections
Interventions
Chloroquine, Placebo
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
15
States / cities
Birmingham, Alabama • San Diego, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2014 · Synced Sep 10, 2026, 4:40 PM EDT
Completed Phase 2 Interventional

Effectiveness of and Immune Response to HIV Vaccination Followed by Treatment Interruption in HIV Infected Patients

NCT00080106
View directory record Official record
Conditions
HIV Infections
Interventions
MRK Ad5 HIV-1 gag vaccine, Vaccine placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
27
States / cities
Los Angeles, California • Palo Alto, California • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Sep 10, 2026, 4:40 PM EDT
Completed Phase 3 Interventional

Effectiveness of a Telephone Intervention Program in Improving Depression, Coping, and Family Functioning in HIV-Infected Individuals and Caregivers

NCT00183781
View directory record Official record
Conditions
HIV Infections
Interventions
FITT: Family Intervention - Telephone Tracking
Behavioral
Lead sponsor
Butler Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 21, 2013 · Synced Sep 10, 2026, 4:40 PM EDT
Completed No phase listed Observational

Immune Response to Seasonal Influenza Vaccine in HIV Infected Individuals

NCT01381029
View directory record Official record
Conditions
Influenza, Human, Human Immunodeficiency Virus I Infection
Interventions
Not listed
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 99 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 18, 2023 · Synced Sep 10, 2026, 4:40 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Reducing the Residual Reservoir of HIV-1 Infected Cells in Patients Receiving Antiretroviral Therapy

NCT02471430
View directory record Official record
Conditions
HIV Infection
Interventions
Panobinostat, Pegylated Interferon-alpha2a
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 27, 2024 · Synced Sep 10, 2026, 4:40 PM EDT
Completed Phase 1 Interventional Results available

Study to Evaluate Safety and Toxicity of Polyphenon E (EGCG) in HIV-1-Infected Individuals

NCT01433289
View directory record Official record
Conditions
HIV Infection
Interventions
Polyphenon E, Placebo
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 18, 2023 · Synced Sep 10, 2026, 4:40 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Studies of HIV-1 Infection in Newly Infected Individuals in Southern Africa

NCT00006298
View directory record Official record
Conditions
HIV Infections, HIV Seronegativity
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 24, 2008 · Synced Sep 10, 2026, 4:40 PM EDT
Withdrawn Phase 3 Interventional

Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone

NCT01605084
View directory record Official record
Conditions
HIV
Interventions
Atazanavir, Darunavir, Ritonavir, Optimized NRTI backbone
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
14
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced Sep 10, 2026, 4:40 PM EDT
Withdrawn Not applicable Interventional

Effect of a Change in HIV Therapy on Liver Steatosis, Inflammation, and Fibrosis

NCT00023218
View directory record Official record
Conditions
HIV Infections, Hepatitis C
Interventions
Lopinavir/Ritonavir, Efavirenz
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
Honolulu, Hawaii • Tripler AMC, Hawaii • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 8, 2015 · Synced Sep 10, 2026, 4:40 PM EDT
Terminated Phase 4 Interventional Results available

Addition of Raltegravir to Established Antiretroviral Suppressive Therapy

NCT01245101
View directory record Official record
Conditions
HIV
Interventions
Raltegravir
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 99 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 22, 2016 · Synced Sep 10, 2026, 4:40 PM EDT
Completed Phase 1 Interventional

Safety and Effectiveness of Immunotherapy With Autologous HIV-Specific CD8 Cells in HIV Infected Adults

NCT00110578
View directory record Official record
Conditions
HIV Infections
Interventions
Adoptive transfer of HIV-specific CD8+ T cells, Aldesleukin
Procedure · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2005
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 7, 2008 · Synced Sep 10, 2026, 4:40 PM EDT
Completed Phase 1 Interventional

3BNC117 and 10-1074 in ART-treated Individuals

NCT03526848
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
3BNC117, 10-1074, Analytical treatment interruption
Drug · Other
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Sep 10, 2026, 4:40 PM EDT
Withdrawn Phase 3 Interventional

Salvage Treatment, Resistance Testing, and Withdrawal of Anti-HIV Drugs for HIV Patients Failing Current Anti-HIV Treatment

NCT00011128
View directory record Official record
Conditions
HIV Infections
Interventions
Antiretroviral Treatment Interruption
Behavioral
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
29
States / cities
Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 17, 2015 · Synced Sep 10, 2026, 4:40 PM EDT
Completed Phase 1 Interventional

Safety of and Immune System Response to an HIV Vaccine (EP HIV-1090) in HIV Infected Patients

NCT00052182
View directory record Official record
Conditions
HIV Infections
Interventions
EP HIV-1090
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 59 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 22, 2007 · Synced Sep 10, 2026, 4:40 PM EDT
Terminated Phase 2 Interventional Results available

Rifabutin Based Therapy for the Eradication of Staphylococcus Aureus Colonization in HIV Infected Adults

NCT00869518
View directory record Official record
Conditions
Staphylococcus Aureus, HIV Infections
Interventions
rifabutin plus trimethoprim sulfamethoxazole, placebo plus trimethoprim-sulfamethoxazole
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 13, 2014 · Synced Sep 10, 2026, 4:40 PM EDT